Clinical Efficacy of Tongxinluo Capsule Combined with Nutritional Support on Coronary Heart Disease Angina Pectoris

This study aimed to explore the impact of the Tongxinluo capsule combined with nutritional support on the clinical efficacy and nutritional status of patients with coronary heart disease angina pectoris. A total of 118 patients admitted to our hospital between August 2022 and May 2023 were divided into a control group and an observation group. Patients in the control group underwent routine treatment and nutritional interventions. Patients in the observation group received Tongxinluo capsules and tailored nutritional treatments. The observation group had a higher total effective rate, left ventricular ejection fraction, and high-density lipoprotein cholesterol level than the control group. Conversely, it had lower left ventricular end-systolic diameter, left ventricular end-diastolic diameter, total cholesterol, triglyceride, and low-density lipoprotein cholesterol levels compared to the control group. Interleukin-6, tumor necrosis factor α, hypersensitive C-reactive protein levels, plasma viscosity, hematocrit, high-cut whole blood viscosity, fibrinogen level, and body mass index of the observation group were also lower than the control group. The incidence of adverse reactions between the two groups was not significant (P > 0.05). Tongxinluo capsule, combined with nutritional support effectively and safely treats coronary heart disease angina pectoris and can improve patients’ cardiac function index.